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COMBINATION THERAPY OF
INTRAVITREAL RANIBIZUMAB AND
SUBTHRESHOLD MICROPULSE
PHOTOCOAGULATION FOR MACULAR
EDEMA SECONDARY TO BRANCH
RETINAL VEIN OCCLUSION
6-MONTH RESULT
HIROKO TERASHIMA, MD,* HIRUMA HASEBE, MD, PHD,* FUMIKI OKAMOTO, MD, PHD,†
NAOKI MATSUOKA, MD, PHD,* YAYOI SATO, MD, PHD,* TAKEO FUKUCHI, MD, PHD*
Purpose: To determine the efﬁcacy of the combination therapy of intravitreal ranibizu-
mab (IVR) and 577-nm yellow laser subthreshold micropulse laser photocoagulation
(SMLP) for macular edema secondary to branch retinal vein occlusion cystoid macular
edema.
Methods: Retrospective, consecutive, case–control study. Forty-six eyes of 46 patients
with treatment-naive branch retinal vein occlusion cystoid macular edema were enrolled.
The IVR + SMLP group consisted of 22 patients who had undergone both SMLP and IVR.
Intravitreal ranibizumab group consisted of 24 patients who had undergone IVR monother-
apy. Intravitreal ranibizumab therapy was one initial injection and on a pro re nata in both
groups, and SMLP was performed at 1 month after IVR in the IVR + SMLP group. Pre-
operatively and monthly, best-corrected visual acuity and central retinal thickness were
evaluated using swept source optical coherence tomography.
Results: Best-corrected visual acuity and central retinal thickness signiﬁcantly improved
at 6 months in IVR + SMLP and IVR groups. Best-corrected visual acuity and central retinal
thickness were not signiﬁcantly different between the two groups at any time points. The
number of IVR injections during initial 6 months in IVR group (2.3 ± 0.9) was signiﬁcantly
greater (P = 0.034) than that in IVR + SMLP group (1.9 ± 0.8).
Conclusion: The combination therapy of IVR and SMLP can treat branch retinal vein
occlusion cystoid macular edema effectively, by decreasing the frequency of IVR injections
while maintaining good visual acuity.
RETINA 39:1377–1384, 2019
Branch retinal vein occlusion (BRVO) is the secondmost common cause of retinal vascular abnormality
after diabetic retinopathy and a frequent cause of visual
loss.1 Branch retinal vein occlusion presents as venous
dilatation or tortuosity, intraretinal hemorrhage, cystoid
macular edema (CME), capillary nonperfusion, and
serous retinal detachment (SRD),2,3 and the most com-
mon vision-threatening pathogenesis are macular edema
with/without SRD in acute phase. Visual acuity is
affected by all of these conditions, but visual loss is
frequently ascribed to CME.4 Therefore, various treat-
ments for BRVO-CME are being addressed.
Vascular endothelial growth factor (VEGF), also
known as vascular permeability factor, is believed to
play an important role in the pathogenesis of BRVO-
CME.2,5–7 Recently, anti-VEGF is recognized as the
main treatment for BRVO-CME, and it has been re-
ported that intravitreal ranibizmab (Lucentis; Genen-
tech, San Francisco, CA) (IVR) treatment is highly
effective at suppressing macular edema.8–10 However,
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according to several studies,11,12 the rate at which
edema can be controlled with a single injection of
anti-VEGF therapy was less than 30% and other cases
require multiple additional injections because of per-
sistent or recurrent edema. Increasing the frequency of
vitreous injections may increase the risk of endoph-
thalmitis and retinal detachment, and the problem of
medical expense will increase in the future. Therefore,
attention has recently been focused on the develop-
ment of new therapeutic methods that suppress the
recurrence of edema rather than on anti-VEGF
monotherapy.
However, traditional retinal laser photocoagulation
in the macula lesion has long been recognized as the
optimal treatment of macular edema by the Branch
Retinal Vein Occlusion Study.13 However, the visual
improvement after laser treatment occurred slowly and
was limited, and conventional laser photocoagulation
may lead to several complications over the long term,
such as enlargement of laser scar,14 subretinal ﬁbro-
sis,15 choroidal neovascularization,16 and ﬁeld sensi-
tivity deterioration,17 which can severely affect visual
function. To reduce these laser complications, advan-
ces in laser technology have led to the development of
selective photocoagulation for the retinal pigment epi-
thelium (RPE) through the subthreshold micropulse
laser photocoagulation (SMLP) method. This is de-
signed to target the RPE, while having a minimal
effect on the sensory retina and choroid. The principle
is to shorten the coagulation time and save the total
amount of energy to reduce invasiveness. Friberg and
Karatza18 ﬁrst reported the clinical application of 810-
nm diode SMLP for diabetic macular edema in 1997.
After that, several clinical studies have since demon-
strated the efﬁcacy of this method for diabetic macular
edema19–22 and BRVO-CME.23–25
One of the more recent developments is the incor-
poration of micropulse laser technology in a 577-nm
yellow laser system, which offers both continuous wave
and micropulse modes and facilitates the conﬁrmation
of the threshold coagulation spot because of a yellow
wavelength. Although this laser system was recently
released domestically in October 2011, few clinical
studies of 577-nm SMLP have been reported for diabetic
macular edema to date.26,27 This laser is effective for
mild macular edema and has a sustained effect without
visible damage. To the best of our knowledge, there have
been no previous reports on anti-VEGF drugs and
577-nm SMLP combination therapy for BRVO-CME.
The purpose of this study is to verify the therapeutic
effects and safety of edema recurrence suppression effect
using 577-nm SMLP in combination with IVR.
Methods
Forty-six eyes of 46 patients with treatment-naïve
BRVO-CME were enrolled. Patients affected by
BRVO observed in the outpatient department of Nii-
gata University Hospital between 2013 August and
2016 June were identiﬁed and invited to enroll pro-
spectively. We tried two treatment methods for
BRVO-CME at two different treatment periods. In
the earlier period (from 2013 August to 2015 January),
combination therapy of IVR and 577-nm SMLP was
performed on 22 patients (IVR + SMLP group), and in
the later period (from 2015 January to 2016 June),
IVR monotherapy was performed on the remaining
24 patients (IVR group). This retrospective, consecu-
tive, single-center, nonrandomized, and case–control
study was approved by the Research Ethics Commit-
tee of Niigata University Hospital before study initi-
ation, and the study followed the tenets of the
Declaration of Helsinki. Before treatment, all patients
had been followed up for at least 2 months after dis-
ease onset, and their CME and/or SRD had persisted.
Inclusion criteria were baseline best-corrected visual
acuity (BCVA) ranged from 20/400 to 20/25 on
Snellen equivalency and central retinal thickness
(CRT), deﬁned as the mean thickness of the central
1-mm diameter disk of the retinal map, exceeded 250
mm as determined by swept source optical coherence
tomography (SS-OCT). Exclusion criteria were coex-
istence of any other retinal disorders, uveitis, presence
of glaucoma, and severe cataracts. We also excluded
patients with previous history of vitreoretinal surger-
ies, intravitreal therapies, or macular grid laser treat-
ment within 6 months before the study and follow-up
period ,6 months. Signed informed consent was ob-
tained from all study subjects.
The examinations included measurements of their
BCVA and retinal microstructures. All ophthalmologic
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examinations were performed before and at 1, 2, 3, 4, 5,
and 6 months after treatment. Best-corrected visual
acuity was measured using the Landolt Chart and was
expressed as the logarithm of the minimum angle of
resolution for statistical analysis. And to express the
changes of BCVA, logarithm of the minimum angle of
resolution BCVA was converted to the Early Treatment
Diabetic Retinopathy Study letter score. Based on fundus
examinations, the patients were classiﬁed as “major
BRVO” and “macular BRVO.” Retinal microstructures
were obtained using SS-OCT (DRI OCT-1; Topcon,
Tokyo, Japan) by way of 12-mm radial scan protocols,
and CRT was recorded for analysis from the retinal
thickness maps. Fluorescein angiographies were per-
formed using the Heidelberg Retina Angiograph system
(Heidelberg Engineering, Heidelberg, Germany) at
before and 6 months after treatment to evaluate nonper-
fusion areas and possible atrophic changes to the RPE
after SMLP.
All patients received an initial IVR, and additional
IVRs were delivered pro re nata (PRN) basis according
to the following retreatment criteria: new or persistent
cystoid retinal changes and SRD, an increase of CRT
.20% after an initial decrease, and a worsening of the
BCVA by .0.2 logarithm of the minimum angle of
resolution units after an initial improvement. The com-
bination therapy group (IVR + SMLP) was treated
with SMLP one month after IVR. Additional SMLP
was performed at intervals of at least 3 months, so if
there was a recurrence at that time (within 3 months
after SMLP), no additional SMLP was performed in
combination and this group was treated with only IVR.
Subthreshold micropulse laser photocoagulation was pro-
vided by a 577-nm yellow laser system (Iridex IQ577;
Laser System Iridex Corp, Mountain View, CA).
Laser application was performed with an Area-
Centralis lens (Volk Optical, Mentor, OH, USA), and
the micropulse laser power used in SMLP was derived
for each eye from a test burn. The test burn was per-
formed in the continuous-wave mode using a 100-mm
spot diameter and 0.2-second exposure outside the vas-
cular arcade with the power titrated from 80 mW
upward until a burn became barely visible. The sub-
threshold treatment was performed by switching the
laser from the continuous-wave to the micropulse
mode, and the laser parameters were 100-mm laser spot
diameter, 0.2-second exposure, and 15% duty cycle.
Multiple laser bursts were delivered to the entire area
affected by the macular edema, avoiding the foveal
center, to provide as tight a coverage as possible with-
out the individual burns actually touching.
The mean scores were compared and SD values
were calculated for each parameter. Statistical analysis
was performed using the Student’s t-test (paired and
unpaired depending on the groups) to evaluate the
changes of BCVA, CRT, and number of IVR. The
chi-square test was applied for the comparison of pro-
portion. The level of statistical signiﬁcance was set at
P , 0.05.
Results
Table 1 shows the baseline clinical characteristics,
visual acuity, and OCT parameters in patients with
BRVO-CME. No differences were observed between
two groups in age, sex, visual acuity, CRT, duration of
symptom from onset, location of vein occlusion, and
occlusion type. No serious ocular or nonocular com-
plications associated with IVR and SMLP were
Table 1. Baseline Clinical Characteristics, Visual Acuity, and OCT Parameters in Patients With Macular Edema Secondary
to BRVO
IVR + SMLP Group (n = 22) IVR Group (n = 24) P
Age (years) 67.9 ± 8.9 68.8 ± 11.9 0.761*
Sex (males/females) 10/12 10/14 0.969†
BCVA; logMAR (range in Snellen
equivalents)
0.45 ± 0.24 (20/200-20/29) 0.53 ± 0.43 (20/400-20/25) 0.463*
BCVA; ETDRS letters 62.2 ± 12.0 58.4 ± 21.3 0.414*
BCVA ≧20/40, no (%) 9 (40.9%) 11 (45.8%) 0.736†
CRT (mm) 515 ± 172 513 ± 1.44 0.924*
Duration of symptom from onset
(months)
2.6 ± 0.8 2.8 ± 1.2 0.665*
Location of vein occlusion (superior/
inferior)
13/9 14/10 0.804†
Occlusion type (major/macular) 15/7 16/8 0.837†
*Student’s t-test.
†Chi-square test.
ETDRS, early treatment diabetic retinopathy study; IVR + SMLP group, the combination therapy group of intravitreal ranibizumab and
577-nm subthreshold micropulse photocoagulation; IVR group, the monotherapy group of intravitreal ranibizumab; logMAR, logarithm of
the minimum angle of resolution.
COMBINATION THERAPY OF IVR&SMLP FOR BRVO  TERASHIMA ET AL 1379
observed in any of the eyes over the entire observa-
tional period. In addition, no laser spots were detected
in any treated areas on SS-OCT ﬁndings and ﬂuores-
cein angiographies.
Time Course of Changes in Best-Corrected Visual
Acuity and Central Retinal Thickness of IVR +
SMLP Group and Intravitreal Ranibizumab Group
Figure 1 reveals time course of changes in visual
acuity in both groups. Best-corrected visual acuity sig-
niﬁcantly improved by the treatment in both group.
Best-corrected visual acuity signiﬁcantly improved at
all time points compared with baseline in IVR +
SMLP group and IVR group (P , 0.001). Central
retinal thickness also showed signiﬁcant improvement
by the treatment in both group. Central retinal thick-
ness signiﬁcantly improved at all time points com-
pared with baseline in IVR + SMLP group and IVR
group (P , 0.001, Figure 2).
Visual and Anatomical Outcomes at 6 Months After
Treatment in IVR + SMLP Group and Intravitreal
Ranibizumab Group
Table 2 shows visual acuity and OCT parameters at
6 months after treatment in IVR + SMLP group and
IVR group. Best-corrected visual acuity (logarithm of
the minimum angle of resolution) at 6 months in the
IVR + SMLP group and IVR groups was 0.11 ± 0.15
(range in Snellen equivalents: 20/50–20/16) and 0.23
± 0.38 (range in Snellen equivalents: 20/400–20/16),
respectively, and was not signiﬁcantly different
between the 2 groups. Best-corrected visual acuity
changes in Early Treatment Diabetic Retinopathy
Study letter score from baseline to 6 months were
not signiﬁcantly different (17.1 ± 11.1 letters in the
IVR + SMLP group and 15.0 ± 14.3 letters in the IVR
group). Twenty of 22 eyes (90.9%) maintained BCVA
.20/40 at 6 months in IVR + SMLP group and 19 of
24 eyes (79.2%) maintained in IVR monotherapy
group. The rate of patients with BCVA .20/40
increased in both groups after 6 months. Central retinal
thickness at 6 months in the IVR + SMLP group and
IVR groups was 296 ± 98 and 341 ± 139, respectively,
and was not signiﬁcantly different between the 2
groups. Eighteen of 22 eyes (81.8%) maintained
CRT ≦300 mm at 6 months in IVR + SMLP group
and 16 of 24 eyes (66.7%) maintained in IVR group.
Required Treatments
The number of IVR injections was 1.9 ± 0.8 in the
IVR + SMLP group and 2.3 ± 0.9 in the IVR group;
there was signiﬁcant difference between the 2 groups
(Table 3). In addition, according to the occlusion type
result, the number of IVR injections in the major
BRVO type (31 eyes) was 2.1 ± 0.7 in the IVR +
SMLP group (15 eyes) and 2.5 ± 0.8 in the IVR group
(16 eyes); there was no statistically signiﬁcant differ-
ence between the 2 groups. And, in the macula BRVO
type (15 eyes), there were no statistically signiﬁcant
differences in the results of seven eyes (1.3 ± 0.5) and
eight eyes (2.0 ± 1.1). Eight of the 22 eyes (36.4%) did
not require PRN-IVR injections during 6 months (= no
recurrence) in IVR + SMLP group and 5 of the 24 eyes
(20.8%) in IVR group. The mean number of SMLP
procedures was 1.4 ± 0.6 in the IVR + SMLP group.
Fig. 1. Time course of changes
in BCVA of IVR + SMLP group
(the combination therapy group
of IVR and 577-nm SMLP) and
IVR group (the monotherapy
group of IVR). Best-corrected
visual acuity signiﬁcantly
improved at all time points
compared with baseline in IVR
+ SMLP group and IVR group
(*P , 0.001).
1380 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES  2019  VOLUME 39  NUMBER 7
Discussion
The IVR & SMLP combination therapy and the IVR
monotherapy had an immediate effect, and all edema
rapidly disappeared at 1 month after treatment and
signiﬁcantly improved visual acuity for 6 months in
BRVO-CME eyes in this study. Visual acuity of com-
bination therapy group was better than that of the
monotherapy group throughout the observation peri-
ods, although there was no signiﬁcant difference
between the two groups. In addition, CRT was signif-
icantly decreased after 1 month from IVR, and the
rates of macular edema (that was controlled at 300
mm or less at 6 months) were 82% in the combination
therapy group and 62% in the monotherapy group.
However, there was no signiﬁcant difference between
two groups. According to Parodi et al,23 threshold grid
laser treatment had a more rapid effect in promoting
the resolution of macular edema because a reduction in
both foveal thickness and total macular volume could
be detected at 6 months from treatment, whereas a sim-
ilar decrease was obtained after 12 months in the
group treated with subthreshold grid laser treatment
with an infrared micropulse diode laser, that is, the
effect of SMLP appears more slowly than the conven-
tional laser treatment. Therefore, as the full effects of
SMLP are generally not apparent until closer to 12
months after treatment, this study cannot show those
effects as clearly because of the shorter 6-month study
period and smaller number of cases, although this
study certainly showed that this combination therapy
had a synergistic effect in promoting macular edema
resolution.
Interestingly, the number of IVR injections required
at 6 months was much lower in the combination
therapy group (1.9 ± 0.8) than that in the IVR
Fig. 2. Time course of changes
in CRT of IVR + SMLP group
(the combination therapy group
of IVR and 577-nm SMLP) and
IVR group (the monotherapy
group of IVR). Central retinal
thickness signiﬁcantly reduced
at all time points compared with
baseline in IVR + SMLP group
and IVR group (*P , 0.001).
Table 2. Visual and Anatomical Outcomes at 6 Months After Treatment in Patients With Macular Edema Secondary to
BRVO
IVR + SMLP Group (n = 22) IVR Group (n = 24) P
BCVA; logMAR (range in Snellen
equivalents)
0.11 ± 0.15 (20/50–20/16) 0.23 ± 0.38 (20/400–20/16) 0.183*
BCVA; ETDRS letters 79.2 ± 7.6 73.4 ± 19.0 0.457*
Change from baseline BCVA in
ETDRS letters
17.1 ± 11.1 15.0 ± 14.3 0.432*
BCVA ≧20/40, no (%) 20 (90.9%) 19 (79.2%) 0.486†
CRT (mm) 296 ± 98 341 ± 139 0.219*
CRT ≦300 mm at 6 months, no (%) 18 (81.8%) 16 (66.7%) 0.405†
*Student’s t-test.
†Chi-square test.
ETDRS, early treatment diabetic retinopathy study; IVR + SMLP group, the combination therapy group of intravitreal ranibizumab and
577 nm subthreshold micropulse photocoagulation; IVR group, the monotherapy group of intravitreal ranibizumab; logMAR, logarithm of
the minimum angle of resolution.
COMBINATION THERAPY OF IVR&SMLP FOR BRVO  TERASHIMA ET AL 1381
monotherapy group (2.3 ± 0.9). In addition, the num-
ber of cases that did not recur at 6 months and where
macular edema was able to be controlled with only one
IVR treatment was 36.4% in the combination therapy
group as compared with 20.8% in the IVR monother-
apy group. In addition, there were fewer cases of early
recurrence (2–3 months) after the ﬁrst IVR in the com-
bination therapy group (54.5%) than in the monother-
apy group (75.0%). Also, the classiﬁcation of
occlusion type (major or macular BRVO) seems to
affect the response to treatment. Therefore, we com-
pared the number of IVR injections by occlusion type,
but although there was no statistically signiﬁcant dif-
ference, combination therapy was less frequent than
IVR monotherapy regardless of occlusion type. Early
recurrence was considered to have been suppressed
using SMLP in combination, which led to a decrease
in the number of IVR injections. If we evaluate it
further for a period longer than 6 months, we may
be able to expect a further decrease in the number of
relapses (reduction in the number of IVR injections)
by combination therapy.
According to the BRIGHTER study,28 the number
of IVR injections required for 6 months was 4.8 ± 1.0
times in the 0.5-mg IVR monotherapy group and 4.5 ±
1.2 times in the IVR + conventional grid laser
treatment group. The administration methods were dif-
ferent between this study and the BRIGHTER study.
The protocol of this study was one injection + PRN; if
there was a loss of visual acuity and the macula status
met the recurrence criteria, only one injection was
administered to the patients in the ranibizumab group.
However, in the BRIGHTER study, if there was a loss
of visual acuity due to disease activity as judged by the
investigator, monthly injections were again adminis-
tered to the patients in the ranibizumab (with or with-
out laser) groups until stability was achieved for three
consecutive months; this required at least two consec-
utive injections. Change in visual acuity from baseline
to 6 months was higher in both groups (IVR + SMLP
group and IVR group) of this study (+17.1 letters and
+15.0 letters, respectively) compared with the
BRIGHTER study (+14.8 letters). However, there
were differences in baseline visual acuity in the two
studies; patients of the IVR + SMLP group in this
study had a higher mean baseline BCVA score (62.2
letters in IVR + SMLP vs. 59.5 letters in the BRIGHT-
ER study). Although it cannot be compared simply
because there are differences in administration method
and baseline visual acuity, a similarly good visual acu-
ity in this combination therapy was obtained as with
the BRIGHTER study and with a smaller number of
IVR injections.
The administration method and subsequent readmi-
nistration criteria are key to decreasing the number of
IVR injections. It was conﬁrmed at this time that
vision can be sufﬁciently maintained even with
administration of 1 + PRN, rather than 3 times in
a row. Regarding readministration criteria, at present,
there is no uniﬁed standard and there are many differ-
ences between facilities. The readministration criteria
adopted this time was performed not only with an
increase in macular edema but also in cases involving
deterioration of visual acuity and SRD recurrence.
Often, clinical practice demonstrates that morphologi-
cal change and functional impairment at the time of
recurrence of BRVO are not necessarily parallel.
Regarding BRVO, unlike the recurrence criteria of
age-related macular degeneration,29,30 the necessity
of prophylactic administration is low and we believe
the PRN method to be enough for macular edema
secondary to BRVO.
Regarding safety and side effects of these treatments,
no sight-threatening ocular adverse events related to
IVR and SMLP were recorded. Subthreshold micro-
pulse photocoagulation was performed 1.4 times for 6
months in the combination therapy group, in all cases,
including cases where 577-nm SMLP was performed
more than once, scarring of the laser as seen in normal
retinal photocoagulation throughout 6 months was not
Table 3. Analysis of Required Treatments
IVR+SMLP Group (n = 22) IVR Group (n = 24) P
No. of IVR injections (range) 1.9 ± 0.8 (1–3) 2.3 ± 0.9 (1–4) 0.034*
No. of IVR injections (range)
Major BRVO (n = 31) 2.1 ± 0.7 (1–3) (n = 15) 2.5 ± 0.8 (1–4) (n = 16) 0.101*
Macula BRVO (n = 15) 1.3 ± 0.5 (1–2) (n = 7) 2.0 ± 1.1 (1–4) (n = 8) 0.060*
Eyes that did not require PRN
injections
8 (36.4%) 5 (20.8%) 0.400†
No. of SMLP procedures (range) 1.4 ± 0.6 (1–3) N/A
*Student’s t-test.
†Chi-square test.
IVR + SMLP group, the combination therapy group of intravitreal ranibizumab and 577-nm subthreshold micropulse photocoagulation;
IVR group, the monotherapy group of intravitreal ranibizumab; N/A, not applicable; PRN, pro re nata.
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detected in color fundus photograph, ﬂuorescein angi-
ography, and SS-OCT. In addition, no patients com-
plained of ocular discomfort after treatment with
SMLP. Laser scarring by SMLP was not conﬁrmed
either in the ﬂattering image at RPE level in the en face
image by SS-OCT. Intravitreal ranibizmab had an
immediate effect, and at 1 month after treatment, all
edema disappeared. By implementing 577-nm SMLP
systematically at the stage where the edema disap-
peared, there was a possibility that the RPE could be
coagulated more selectively and efﬁciently.
Limitations of this study included being non-
randomized and open label, a nonparallel group study
with a short duration, and a small population. Despite
this, the results of this study suggest that 577-nm
SMLP is an effective option of IVR treatment of
macular edema secondary to BRVO, and randomized
clinical trials are warranted to determine the optimal
treatment interval, duration, duty cycle, and laser
power. And, the difference in the number of injections
was statistically signiﬁcant, although only compared
during a short period of 6 months, so the effects of
signiﬁcantly reducing the number of IVR by combi-
nation therapy of SMLP are not yet perfectly under-
stood. However, we hope that further study can
identify better indications in the future.
In conclusion, the combination therapy of IVR and
577-nm SMLP can treat macular edema secondary to
BRVO effectively and safely, by decreasing the
frequency of IVR while maintaining good visual
acuity.
Key words: macular edema, branch retinal vein
occlusion, intravitreal ranibizumab, 577-nm subthresh-
old micropulse photocoagulation.
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